We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Autonomous Blood Drawing Device Combines AI, Ultrasound Imaging and Robotics

By LabMedica International staff writers
Posted on 02 Jun 2022

Within healthcare, the clinical laboratory is the driving force. More...

Accuracy and timeliness of laboratory tests are critically important, as they shape approximately 70% of all medical decisions made by physicians. It is unsurprising that blood collection (phlebotomy) is the most common invasive medical procedure, performed billions of times per year globally. Blood collection holds a pivotal role in clinical diagnostics yet is also burdened by the scarcity of skilled workers. Now, an autonomous blood drawing device, combining artificial intelligence, ultrasound imaging and robotics, automates this labor-intensive procedure to transform the quality of care and create a sustainable healthcare system.

Vitestro (Utrecht, the Netherlands) has unveiled the world’s most advanced autonomous blood drawing device that combines AI-based, ultrasound-guided 3D reconstruction with robotic needle insertion, ensuring accurate and secure blood collection. Vitestro’s proprietary laboratory automation technology standardizes handling of the blood sample while the blood is collected. The device allows almost complete automation of the pre-analytical phase. This has the potential to reduce high blood test error rates, mainly caused by manual variability. In clinical studies, Vitestro already performed 1,500 automated blood draws in more than 1,000 patients with its prototype. The venipuncture technology is adaptable to patients of 16 years of age onwards, comorbidities, and puncture difficulty.

From 2023, Vitestro will initiate pivotal clinical studies for regulatory approval in Europe. EU-market introduction is anticipated in 2024. Vitestro will initially implement the device in outpatient phlebotomy departments. Patients will have the option to choose between either Vitestro’s venipunture device or the standard method. The device is intuitive to use, empowering patients to be self-reliant in the full blood collection procedure. In previous clinical trials, patients of all ages have demonstrated a high degree of openness, enthusiasm and willingness to adopt the innovation. A trained healthcare professional is able to supervise several devices, managing multiple patients simultaneously. The increased efficiency enables hospitals and clinical laboratories to address workforce shortage or even free up staff and deploy them where they are really needed.

“The mounting shortage of healthcare personnel is imminent,” said Toon Overbeeke, Vitestro’s Co-Founder and Chief Executive Officer. “The pandemic has further led to loss of workforce, causing a bleak outlook for hospital output around the globe, and leading to reduced access and continuity of care. That's why revolutionary automation like our blood drawing device is inevitable to solve the industry's biggest problem.”

Related Links:
Vitestro 


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Gold Member
Troponin T QC
Troponin T Quality Control
New
Clostridium Difficile Test
Immunocard Toxins A&B
New
Silver Member
Cell and Tissue Culture Plastics
Diamond® SureGro™ Cell and Tissue Culture Plastics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The POC device rapidly predicts neonatal respiratory disease at birth in the NICU (Photo courtesy of SIME Diagnostics)

AI-Powered Lung Maturity Test Identifies Newborns at Higher Risk of Respiratory Distress

Each year, approximately 300,000 babies in the United States are born between 32 and 36 weeks' gestation, according to national health data. This group is at an elevated risk for respiratory distress,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Custom hardware and software for the real-time detection of immune cell biophysical signatures in NICU (Photo courtesy of Pediatric Research, DOI:10.1038/s41390-025-03952-y)

First-Of-Its-Kind Device Profiles Newborns' Immune Function Using Single Blood Drop

Premature infants are highly susceptible to severe and life-threatening conditions, such as sepsis and necrotizing enterocolitis (NEC). Newborn sepsis, which is a bloodstream infection occurring in the... Read more

Pathology

view channel
Image: Results of AI-based 3D virtual H&E staining and quantitative analysis of pathological tissue (Photo courtesy of Nature Communications, DOI:10.1038/s41467-025-59820-0)

Virtual Staining Technology Paves Way for Non-Invasive Pathological Diagnosis

For more than 200 years, traditional pathology has depended on the technique of examining cancer tissues under a microscope, a method that provides only limited, specific cross-sections of the 3D structure... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.